Role of CYP2E1 in the mouse model of MPTP toxicity

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Pardini, Carla ^a   Vaglini, Francesca ^a   Viaggi, Cristina ^a   Caramelli, Andrea ^a   Corsini, Giovanni U ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CYP2E1; DAS; DDC; MPP+; Neurodegeneration; Neurotoxicity; Parkinson's disease; PIC

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALLYL SULFIDE; CYTOCHROME P450 2E1; DIETHYLDITHIOCARBAMIC ACID; DOPAMINE; MULTIDRUG RESISTANCE PROTEIN 1; PARACETAMOL; PHENYL ISOTHIOCYANATE;

ARTICLE; CORPUS STRIATUM; DETOXIFICATION; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIVER INJURY; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; WILD TYPE; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MICE; MICE, KNOCKOUT; MPTP POISONING;

EID: 47049118556     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.014     Document Type: Article

References (38)

1. Davis C.G., Williams A.C., Markey S.P., Ebert M.H., Calne D.B., Reichert C.M., et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1 (1979) 249-254
2. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
3. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
4. Tursky L., Bressler K., Rettig K.J., Loshmann P.A., and Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349 (1991) 414-418
5. Burns R.A., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowicz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80 (1983) 4546-4550
6. Ricaurte G.A., Langston J.W., DeLannery L.E., Irwin I., Peroutka S.J., and Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376 (1986) 117-124
7. Johannessen J.N. A model for chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenyl-pyridinium (MPP+) within catecholaminergic neurons. Neurotoxicology 12 (1991) 285-302
8. Kopin I.J. Mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons. In: Herken H., and Hucho F. (Eds). Handbook of experimental pharmacology: selective neurotoxicity vol. 102 (1992), Springer, Berlin, Heidelberg New York 333-356
9. Corsini G.U., Maggio R., and Vaglini F. Molecular and cellular events regulating dopamine neuron survival. In: Di Chiara G. (Ed). Handbook of experimental pharmacology: dopamine in the CNS II vol. 154 (2002), Springer-Verlag, Berlin, Heidelberg 321-386
10. Chiba K., Trevor A., and Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120 (1984) 1228-1232
11. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.A., and Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
12. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36 (1985) 2503-2508
13. Ramsay R.R., and Singer T.P. Energy-dependent uptake of 1-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261 (1986) 7885-7887
14. Corsini G.U., Pintus S., Chiueh C.C., Weiss J.F., and Kopin I.J. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol 119 (1985) 127-128
15. Corsini G.U., Zuddas A., Bonuccelli U., Schinelli S., and Kopin I.J. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. Life Sci 40 (1987) 827-832
16. Irwin I., Langston J.W., and DeLanney L.E. 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity. Life Sci 40 (1987) 731-738
17. Giovanni A., Sieber B.A., Heikkila R.E., and Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenyl-pyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 257 (1991) 691-697
18. Zuddas A., Fascetti F., Corsini G.U., and Piccardi P. In Brown Norway rats, MPP+ is accumulated in nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of neural resistance to MPTP toxicity. Exp Neurol 127 (1994) 54-61
19. Di Monte D.A., Wu E.Y., Irwin I., DeLanney L.E., and Langston J.W. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia 5 (1992) 48-55
20. Russ H., Gliese M., Sonna J., and Shomig E. The extraneuronal transport mechanism for noradrenaline (uptake 2) avidly transports 1-methyl-4-phenylpyridinium (MPP+). Naunyn Schmiedebergs Arch Pharmacol 346 (1992) 158-165
21. Giovanni A., Sieber B.A., Heikkila R.E., and Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Part 1: systemic administration. J Pharmacol Exp Ther 270 (1994) 1000-1007
22. Giovanni A., Heikkila R.E., and Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 270 (1994) 1008-1014
23. Vaglini F., Fascetti F., Tedeschi D., Cavalletti M., Fornai F., and Corsini G.U. Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 5 (1994) 129-136
24. Ravindranath V., Anandatheerthavarada H.K., and Shankar S.K. Xenobiotic metabolism in human brain presence of cytochrome P-450 and associated mono-oxygenases. Brain Res 496 (1989) 331-335
25. Warner M., Wyss A., Yoshida S., and Gustafsson J.A. Cytochrome P450 enzymes in brain. Methods in neurosciences vol. 22 (1994), Academic Press, New York 51-66
26. Watts P.M., Riedl A.G., Douek D.C., Edwards R.J., Boobis A.R., and Jenner P. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 86 (1998) 511-519
27. Lieber C.S. Mechanism of ethanol induced hepatic injury. Pharmacol Ther 46 (1990) 1-41
28. Parkinson A. Biotransformation of xenobiotics. In: Klaassen (Ed). Casarett and Doull's toxicology: the basic science of poison. 5th ed. (1996), McGraw-Hill, New York, St. Louis, San Franciso 113-186
29. Stott I., Murthy A., Robinson A., Thomas N.W., and Fry J.R. Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-dichloro-2-propanol and selectively inhibits CYP2E1 activity in the rat. Hum Exp Toxicol 16 (1997) 262-266
30. Vaglini F., Pardini C., Viaggi C., Bartoli C., Dinucci D., and Corsini G.U. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. J Neurochem 91 (2004) 285-298
31. Irwin I., Wu E.Y., DeLanney L.E., Trevor L., and Langston J.W. The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur J Pharmacol 141 (1987) 209-217
32. Zuddas A., Corsini G.U., Schinelli S., Barker J.L., Kopin I.J., and Di Porzio U. Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum. Brain Res 501 (1989) 11-22
33. Barlow B.K., Thiruchelvam M.J., Bennice L., Cory-Slechta D.A., Ballatori N., and Richfield E.K. Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J Neurochem 85 (2003) 1075-1086
34. Doolen S., and Zahniser N.R. Protein tyrosine kinase inhibitors alter human dopamine transporter activity in xenopus oocytes. J Pharmacol Exp Ther 296 (2001) 931-938
35. Niznik H.B., Tyndale R.F., Sallee F.R., Gonzalez F.J., Hardwick J.P., and Inaba T. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 276 (1990) 424-432
36. Kim R.B. Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. Adv Drug Deliv Rev 54 (2002) 1241-1242
37. Lee S.S., Buters J.T., Pineau T., Fernandez-Salguero P., and Gonzalez F.J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271 (1996) 12063-12067
38. Viaggi C., Vaglini F., Pardini C., and Corsini G.U. Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity. J Neural Transm 70 Suppl (2006) 173-176